Companies › Joint & Vascular Institute
1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lipiodol transient liquid embolic agent for lateral plantar artery embolization | – | Phase 1 | Plantar Fasciitis, Chronic; Osteoarthritis | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07395128 | Lipiodol | Phase 1 | Plantar Fasciitis, Chronic | Other | Mar 2027 |
| NCT06611007 | Lipiodol | Phase 1 | Osteoarthritis | Immunology | Jul 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.